Systemic Inflammatory Response Syndrome Clinical Trial
Official title:
Autonomic Nervous Activity During the Systemic Inflammatory Response in Trained and Untrained Healthy Volunteers
Critical illness, severe infection, extensive trauma or tissue damage cause an inflammatory
(irritative) reaction in the body. This reaction affects the whole body and causes malaise,
circulatory and cardiac changes, fever, increases the number of white blood cells in the
blood stream and prompts release of signaling proteins. This reaction contributes to the
development of considerable organ damage and possibly organ failure. These are serious
complications in critical illness which are associated with a high mortality. This
inflammatory reaction is affected by the autonomic nervous system. This is the part of the
nervous system, which is beyond the control of the free will, and the part that regulates
circulation, breathing and digestive functions. The autonomic nervous system works via
so-called sympathetic signals, which set the body in a state of alertness to overcome
immediate challenges, and parasympathetic (vagal) signals, which are especially active
during restitution and rest. It is known, that the balanced activity in the autonomic
nervous system affects the body's inflammatory response in critical illness. A study in mice
has shown that if parasympathetic (vagal) signals are blocked mortality in critical illness
is increased. Reversely, when the autonomic nervous system is medically stimulated towards
parasympathetic signaling, the magnitude of the inflammatory response is decreased. Nicotine
exerts this stimulatory effect.
Also, we know that individuals in good physical shape have increased parasympathetic tone
compared to less trained individuals. However, studies have never addressed whether this
shifted balance in the autonomic nervous system affects the inflammatory response related to
critical illness.
Over the last 30 years an experimental model mimicking the inflammatory response has been
used in studies. Inflammation may be simulated by injecting the drug E.Coli LPS, which
induces a controlled, fully reversible, harmless reaction the duration of which is a few
hours. Influenza-like symptoms occur and changes in circulatory parameters and
concentrations of signaling proteins can be measured.
Using this experimental model, the investigators wish to study whether this shifted balance
in the autonomic nervous system in individuals in good physical shape affects the body's
reaction to critical illness. Investigators also want to determine how nicotine (using a
nicotine patch) affects this reaction.
Aim
The investigators wish to study the inflammatory response in very well-trained and
relatively untrained healthy volunteers using the human endotoxemia model. Also, the
investigators wish to study the effect on nicotine on the inflammatory response..
Background
1. Systemic inflammation and the endotoxin model
Inflammation is the organisms response to invasion of microorganisms, trauma, endogenic
or exogenic tissue damage. Systemic inflammation is a generalized response which
affects the entire organism and presents with symptoms (malaise, shivering, dizziness,
nausea), clinical manifestations (fever, tachypnea and hypocapnia, tachycardia) and
biochemical findings such as altered numbers and relative composition of leucocytes in
blood and increased concentrations of acute phase reactants and cytokines. Systemic
inflammation, activated cascades and microcirculatory disruptions are considered
important pathogenic elements ind the development of organ dysfunction, which is a
frequent and serious complication to critical illness regardless of the underlying
cause.
Over the last 30 years the human endotoxemia model has been us as an experimental
platform for studies of systemic inflammation. Since the year 1998 studies using this
model have been conducted at Center for Inflammation and Metabolism (CIM),
Rigshospitalet, Copenhagen University Hospital. An IV-bolus or infusion of
E.Coli-lipopolysaccharide (LPS), an isolated component of the outer cell wall of
Gram-negative bacteria, also referred to as endotoxin, is administered to healthy
volunteers. A dose-dependent, fully reversible response is evoked the duration of which
is a few hours with flu-like symptoms and production of pro- and anti-inflammatory
markers, e.g tumor-necrosis-factor-α (TNF), interleukin(IL)-1β, IL-6, IL-1ra and IL-10.
Serious adverse events have not been observed. The model is no accurate replication of
acute infection, sepsis or other critical illness, however, evokes a reproducible,
inter-individually comparable and fully reversible inflammatory response, which allows
experimental studies of early stages of acute systemic inflammation and the interplay
between different aspects of critical illness complicated by systemic inflammation.
2. The autonomic nervous system and the inflammatory response
Activity in the autonomic nervous system affects the inflammatory response. Vagal
stimulation inhibits release of pro-inflammatory cytokines, TNF-α, IL-1, IL-6 and high
mobility group box protein-1 (HMGB-1), from macrophages activated by endotoxin,
however, does not inhibit anti-inflammatory IL-10. Cytologic studies document, that
this effect is mediated via the nicotinergic α7-subtype acetylcholine-receptor
(α7nAchR). In a murine model peripheral vagal stimulation in vivo decreased mortality
in endotoxemia and sepsis by cecal ligation.
Kox et al found, that GTS-21 - a specific α7nAchR-agonist - was not generally
associated with an altered inflammatory response in human endotoxemia, however,
identified negative correlation between plasma concentrations of GTS-21 in the
intervention group and maximal TNF-concentration.
In another study, transdermally administered nicotine in healthy volunteers reduced the
clinical, inflammatory response with reduced changes in body temperature and heart rate
and increased plasma concentrations of cortisol and the anti-inflammatory IL-10. No
differences in TNF-α, IL-1 or IL-6 expression were detected.
3. Heart rate variability
Heart rate variability (HRV) is the variation in the interval between successive heart
beats over time. It is a well-described phenomenon and is believed to reflect the
cardiac balance of sympathetic- and vagal activity, thus changes in HRV may be
interpreted as an indirect marker of changes in autonomic nervous activity.
Physiological or pathological changes in autonomic nervous activity can be observed
with performance of a standardized valsalva maneuver while monitoring blood pressure,
heart rate and subsequent calculation of HRV and blood pressure variability.
Reduced HRV is present in critical illness and is believed to reflect a shift in
autonomic nervous balance towards increased sympathetic activity and vagal withdrawal.
This phenomenon is a well documented predictor for poor outcome. Equally, reduced heart
rate variability is observed in human endotoxemia in healthy volunteers. However, the
magnitude of this reduction in HRV does not correspond to the severity of the
inflammatory response as determined by plasma concentrations of pro-inflammatory
cytokines.
Individuals in excellent training status present altered activity in the autonomic
nervous system with increased vagal activity with a low resting heart rate and
increased HRV. Whether this altered autonomic activity still presents during critical
illness is unknown, but it is a possibility that certain positive effects of physical
activity may in part be due increased vagal activity and alterations in the systemic
inflammatory response mediated by the vagal activity.
4. Exercise and the inflammatory response
No previous in vivo studies address the impact of increased vagal activity in well-trained
individuals on the inflammatory response in comparison to that seen in untrained
individuals. In the above mentioned study by Jan et al analysis of baseline HRV found that
and HRV component traditionally considered proportional to sympathetic activity (LF/HF)
correlated inversely with maximal TNF-α concentration in plasma. Furthermore, this study
finds that heart rate at baseline does not correlate to HRV characteristics neither at
baseline nor during endotoxemia. However, physical training condition of the participants is
not reported.
Likewise, no mention of physical training status is made in the before mentioned studies
concerning experimental use of nicotinergic agonist in endotoxemia (transdermally
administered nicotine29 or orally administered GTS-21).
Two in vitro trials perform whole blood stimulation with LPS and find that baseline HRV is
inversely proportional to TNF and IL-6 production, and inflammatory response in vitro is
reduced in previously untrained individuals after a period of regular aerobic exercise. No
in vivo studies addressing this have been conducted.
The investigators aim to study the inflammatory response in endotoxemia in well-trained and
untrained healthy volunteers and determine whether transdermally administered nicotine
alters this response.
A cross-over study design is applied so that volunteers act as their own control. This
increases the chances of demonstrating a statistically significant effect.
Due to risk of LPS-tolerance the two study days need to be at least 4 weeks apart.
Hypotheses
1. Healthy well-trained individuals produce a reduced inflammatory response during
experimental endotoxemia compared to untrained individuals.
2. Healthy, well-trained individuals display an increased HRV at baseline and experience a
smaller reduction in HRV during endotoxemia compared to untrained individuals.
3. Transdermally administered nicotine during endotoxemia reduces clinical and preclinical
features of the inflammatory response during endotoxemia in well-trained as well as
untrained individuals.
4. Endotoxemia induces a transitory state of hyperalgesia in well-trained as well as
untrained volunteers.
;
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02518087 -
Increased Adsorption Membranes During Cardiopulmonary Bypass
|
N/A | |
| Completed |
NCT02902939 -
Myeloid-Derived Supressor Cells in Cardiac Surgery Patients
|
N/A | |
| Completed |
NCT02563652 -
Can Biomarkers Aid in the Prediction of Postoperative Pain and Circulatory Instability After Major Abdominal Surgery?
|
||
| Recruiting |
NCT01157299 -
Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO
|
N/A | |
| Completed |
NCT01388725 -
Comparison the Value of Several Biomarkers of Sepsis
|
N/A | |
| Unknown status |
NCT00254176 -
Cysteine Supplementation in Critically Ill Neonates
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT03617796 -
Prognostic Value of CD64 Marker for Patients in Intensive Care Unit
|
||
| Completed |
NCT03876041 -
Evaluation of Corticosteroid in Systemic Inflammatory Response Syndrome
|
Phase 4 | |
| Recruiting |
NCT05608096 -
European Registry for Hemadsorption in Sepsis With the Seraph Filter
|
||
| Completed |
NCT03314831 -
The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis
|
||
| Completed |
NCT02568410 -
Platelets as Regulators of Inflammation in Cardiac Surgery
|
||
| Completed |
NCT01636232 -
Vitamin D and Critically Ill Patients
|
N/A | |
| Completed |
NCT01020409 -
INFLACOR - Clinical and Genetic Predictors of Inflammation Related Complications After Heart Surgery
|
Phase 4 | |
| Completed |
NCT04624776 -
Steroid Treatment After Resuscitated Out-of-Hospital Cardiac Arrest
|
Phase 2 | |
| Recruiting |
NCT05172739 -
Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in Elective VATS-Lobectomy for NSCLC
|
Phase 4 | |
| Recruiting |
NCT02957175 -
Immunophenotyping of Patients With Postoperative SIRS
|
||
| Completed |
NCT02320539 -
MicroRNA Diagnostics in Subarachnoid Hemorrhage 2
|
N/A | |
| Completed |
NCT01708759 -
IL8 Monitoring and Its Correlation With 251-gene Polymorphism
|
N/A | |
| Terminated |
NCT00708799 -
Efficacy of Macrolide Immunomodulation in Severe Sepsis.
|
Phase 2 | |
| Recruiting |
NCT04580680 -
Extracorporeal Blood Purification Therapy in Critically Ill Patients (GlobalARRT)
|